<DOC>
	<DOC>NCT00522808</DOC>
	<brief_summary>The purposes of this study are: - to determine the safety and tolerability of multiple doses of A-831 at various doses - to determine how multiple doses of A-831 are distributed through the bloodstream - to determine if A-831 reduces the amount of Hepatitis C virus in the blood</brief_summary>
	<brief_title>A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Volunteers will be males of any race aged 1860 years with a BMI between 18 and 32 kg/m2 at the time of the screening medical Volunteers who have given their written informed consent to participate in the study Volunteers who are willing and able to comply with the protocol and study procedures Volunteers who have a diagnosis of chronic hepatitis C infection and are in good health (other than history of Hepatitis C infection) Voulnteers with concurrent medical conditions or taking concurrent medications</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>HCV</keyword>
	<keyword>antiviral</keyword>
	<keyword>PK</keyword>
	<keyword>Safety</keyword>
</DOC>